{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:05:05Z","timestamp":1786460705931,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/638"],"award-info":[{"award-number":["20\/638"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["21\/030"],"award-info":[{"award-number":["21\/030"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/638"],"award-info":[{"award-number":["20\/638"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001552","name":"Cancer Research Trust New Zealand","doi-asserted-by":"publisher","award":["CRTNZ 2012"],"award-info":[{"award-number":["CRTNZ 2012"]}],"id":[{"id":"10.13039\/501100001552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in the tumour suppressor,\n                    <jats:italic>TP53<\/jats:italic>\n                    , are prevalent in human cancers yet their functional implications remain unclear. Through comprehensive pan-cancer database analysis, we identified H179 mutations in\n                    <jats:italic>TP53<\/jats:italic>\n                    as significantly associated with poor disease-free survival across multiple cancer types. Functional studies in lung, ovarian, and prostate cancer cells over-expressing the p53\n                    <jats:sup>H179R\/Y<\/jats:sup>\n                    mutants revealed that these mutants are not only defective in tumour-suppressive functions but also actively promote tumour progression. These mutants drive metabolic reprogramming by increasing neutral lipid levels through de novo fatty acid synthesis (p53\n                    <jats:sup>H179R\/Y<\/jats:sup>\n                    ) and fatty acid uptake (p53\n                    <jats:sup>H179Y<\/jats:sup>\n                    ), accompanied by increased lipid droplets and APOE expression, collectively promoting enhanced invasiveness relative to p53-null cells. Our findings demonstrate that\n                    <jats:italic>TP53<\/jats:italic>\n                    missense mutations are not functionally equivalent to\n                    <jats:italic>TP53<\/jats:italic>\n                    loss. Notably, H179 mutations act as oncogenic drivers, and our data highlight APOE and lipid metabolism as potential therapeutic targets, underscoring the clinical relevance of precise\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation characterisation.\n                  <\/jats:p>","DOI":"10.1038\/s41417-026-01045-4","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:33:32Z","timestamp":1780659212000},"page":"775-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-8875","authenticated-orcid":false,"given":"Debina","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-9272","authenticated-orcid":false,"given":"Gaurav C.","family":"Gyanwali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishree","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2747-009X","authenticated-orcid":false,"given":"Polina","family":"Shevchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jeffs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-5281","authenticated-orcid":false,"given":"Adele G.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sardari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeksha","family":"Bhandarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Ratajska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhdoom","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9539-5249","authenticated-orcid":false,"given":"Srinivasaraghavan","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-6876","authenticated-orcid":false,"given":"Cushla","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisha","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally P.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-5036","authenticated-orcid":false,"given":"Antony","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-1245","authenticated-orcid":false,"given":"Sunali","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"1045_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15\u20136.","journal-title":"Nature"},{"key":"1045_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","volume":"119","author":"GA Lang","year":"2004","unstructured":"Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861\u201372.","journal-title":"Cell"},{"key":"1045_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847\u201360.","journal-title":"Cell"},{"key":"1045_CR4","doi-asserted-by":"crossref","unstructured":"Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. In: Advances in cancer research. Elsevier, 1999, p. 81\u2013137.","DOI":"10.1016\/S0065-230X(08)60785-X"},{"key":"1045_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35:672\u201388.","journal-title":"Hum Mutat"},{"key":"1045_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome Atlas. Cell Rep. 2019;28:1370\u201384.e5.","journal-title":"Cell Rep"},{"key":"1045_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"1045_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.75","volume":"5","author":"J Xu","year":"2014","unstructured":"Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H, et al. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis. 2014;5:e1108.","journal-title":"Cell Death Dis"},{"key":"1045_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/path.4321","volume":"232","author":"N Parikh","year":"2014","unstructured":"Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014;232:522\u201333.","journal-title":"J Pathol"},{"key":"1045_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.18632\/oncotarget.13483","volume":"8","author":"X Wang","year":"2016","unstructured":"Wang X, Sun Q. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2016;8:624\u201343.","journal-title":"Oncotarget"},{"key":"1045_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","volume":"129","author":"P Malekzadeh","year":"2019","unstructured":"Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Investig. 2019;129:1109\u201314.","journal-title":"J Clin Investig"},{"key":"1045_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Mizuno H, Zhao X, Langer\u00f8d A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148:244\u201358.","journal-title":"Cell"},{"key":"1045_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.molcel.2014.04.024","volume":"54","author":"G Zhou","year":"2014","unstructured":"Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell. 2014;54:960\u201374.","journal-title":"Mol Cell"},{"key":"1045_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41556-017-0009-8","volume":"20","author":"E Ingallina","year":"2018","unstructured":"Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, et al. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Nat Cell Biol. 2018;20:28\u201335.","journal-title":"Nat Cell Biol"},{"key":"1045_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42458-1","volume":"14","author":"C Tombari","year":"2023","unstructured":"Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al. Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Nat Commun. 2023;14:6777.","journal-title":"Nat Commun"},{"key":"1045_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43018-3","volume":"14","author":"C Tombari","year":"2023","unstructured":"Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al. Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Nat Commun. 2023;14:7129.","journal-title":"Nat Commun"},{"key":"1045_CR17","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1021\/bi026635n","volume":"42","author":"JS Butler","year":"2003","unstructured":"Butler JS, Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 2003;42:2396\u2013403.","journal-title":"Biochemistry"},{"key":"1045_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469\u201383.","journal-title":"Cancer Cell"},{"key":"1045_CR19","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","volume":"97","author":"G Liu","year":"2000","unstructured":"Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA. 2000;97:4174\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204610119","volume":"119","author":"Correction for Morton.","year":"2022","unstructured":"Correction for Morton. Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc Natl Acad Sci USA. 2022;119:e2204610119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17596-5","volume":"11","author":"V Capaci","year":"2020","unstructured":"Capaci V, Bascetta L, Fantuz M, Beznoussenko GV, Sommaggio R, Cancila V, et al. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat Commun. 2020;11:3945.","journal-title":"Nat Commun"},{"key":"1045_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/cdd.2010.94","volume":"18","author":"I Kogan-Sakin","year":"2011","unstructured":"Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011;18:271\u201381.","journal-title":"Cell Death Differ"},{"key":"1045_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/carcin\/bgr270","volume":"33","author":"WA Yeudall","year":"2012","unstructured":"Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 2012;33:442\u201351.","journal-title":"Carcinogenesis"},{"key":"1045_CR24","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1038\/onc.2016.518","volume":"36","author":"M Escoll","year":"2017","unstructured":"Escoll M, Gargini R, Cuadrado A, Anton IM, Wandosell F. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP\/TAZ. Oncogene. 2017;36:3515\u201327.","journal-title":"Oncogene"},{"key":"1045_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41388-017-0060-8","volume":"37","author":"H Solomon","year":"2018","unstructured":"Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, et al. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. 2018;37:1669\u201384.","journal-title":"Oncogene"},{"key":"1045_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13542-2","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Wang Q, Yu H, Capitano ML, Vemula S, Nabinger SC, et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nat Commun. 2019;10:5649.","journal-title":"Nat Commun"},{"key":"1045_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3667","volume":"4","author":"A Ali","year":"2013","unstructured":"Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, et al. Differential regulation of the REG\u03b3-proteasome pathway by p53\/TGF-\u03b2 signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667.","journal-title":"Nat Commun"},{"key":"1045_CR28","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.18632\/oncotarget.1831","volume":"5","author":"VK Kolukula","year":"2014","unstructured":"Kolukula VK, Sahu G, Wellstein A, Rodriguez OC, Preet A, Iacobazzi V, et al. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget. 2014;5:1212\u201325.","journal-title":"Oncotarget"},{"key":"1045_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/cdd.2015.133","volume":"23","author":"SK Alam","year":"2016","unstructured":"Alam SK, Yadav VK, Bajaj S, Datta A, Dutta SK, Bhattacharyya M, et al. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 2016;23:707\u201322.","journal-title":"Cell Death Differ"},{"key":"1045_CR30","doi-asserted-by":"crossref","unstructured":"Blanden AR, Yu X, Blayney AJ, Demas C, Ha JH, Liu Y et al. Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants. Elife. 2020;9:e61487.","DOI":"10.7554\/eLife.61487"},{"key":"1045_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113.","journal-title":"Nat Genet"},{"key":"1045_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u201313.","journal-title":"Nat Med"},{"key":"1045_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/onc.2008.400","volume":"28","author":"KA Malecka","year":"2009","unstructured":"Malecka KA, Ho WC, Marmorstein R. Crystal structure of a p53 core tetramer bound to DNA. Oncogene. 2009;28:325\u201333.","journal-title":"Oncogene"},{"key":"1045_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","volume":"5","author":"FCE Vogel","year":"2024","unstructured":"Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024;5:16\u201329.","journal-title":"Nat Cancer"},{"key":"1045_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41580-018-0085-z","volume":"20","author":"JA Olzmann","year":"2019","unstructured":"Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20:137\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1045_CR36","doi-asserted-by":"crossref","unstructured":"Petan T, Jarc E, Jusovi\u0107 M. Lipid droplets in cancer: guardians of fat in a stressful World. Molecules 2018;23:1941.","DOI":"10.3390\/molecules23081941"},{"key":"1045_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836058","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yu W, Li S, Guo D, He J, Wang Y. Acetyl-CoA carboxylases and diseases. Front Oncol. 2022;12:836058.","journal-title":"Front Oncol"},{"key":"1045_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","volume":"72","author":"Y Huang","year":"2014","unstructured":"Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases. Neurobiol Dis. 2014;72:3\u201312.","journal-title":"Neurobiol Dis"},{"key":"1045_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31484-0","volume":"13","author":"A Lerma Clavero","year":"2023","unstructured":"Lerma Clavero A, Boqvist PL, Ingelshed K, Bosdotter C, Sedimbi S, Jiang L, et al. MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia. Sci Rep. 2023;13:4583.","journal-title":"Sci Rep"},{"key":"1045_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-11-23","volume":"11","author":"DA Elliott","year":"2010","unstructured":"Elliott DA, Halliday GM, Garner B. Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neurosci. 2010;11:23.","journal-title":"BMC Neurosci"},{"key":"1045_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.neuron.2023.12.018","volume":"112","author":"MR Strickland","year":"2024","unstructured":"Strickland MR, Rau MJ, Summers B, Basore K, Wulf J 2nd, Jiang H, et al. Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins. Neuron. 2024;112:1100\u20131109.e5.","journal-title":"Neuron"},{"key":"1045_CR42","doi-asserted-by":"publisher","first-page":"13161","DOI":"10.2147\/CMAR.S284115","volume":"12","author":"H Wang","year":"2020","unstructured":"Wang H, Du S, Cai J, Wang J, Shen X. Apolipoprotein E2 promotes the migration and invasion of pancreatic cancer cells via activation of the ERK1\/2 Signaling Pathway. Cancer Manag Res. 2020;12:13161\u201371.","journal-title":"Cancer Manag Res"},{"key":"1045_CR43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1091\/mbc.e10-08-0699","volume":"22","author":"BT Helfand","year":"2011","unstructured":"Helfand BT, Mendez MG, Murthy SN, Shumaker DK, Grin B, Mahammad S, et al. Vimentin organization modulates the formation of lamellipodia. Mol Biol Cell. 2011;22:1274\u201389.","journal-title":"Mol Biol Cell"},{"key":"1045_CR44","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41388-023-02703-9","volume":"42","author":"AL Berr","year":"2023","unstructured":"Berr AL, Wiese K, Dos Santos G, Koch CM, Anekalla KR, Kidd M, et al. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer. Oncogene. 2023;42:2074\u201387.","journal-title":"Oncogene"},{"key":"1045_CR45","first-page":"1545","volume":"36","author":"A Tadokoro","year":"2016","unstructured":"Tadokoro A, Kanaji N, Liu D, Yokomise H, Haba R, Ishii T, et al. Vimentin regulates invasiveness and is a poor prognostic marker in non-small cell lung cancer. Anticancer Res. 2016;36:1545\u201351.","journal-title":"Anticancer Res"},{"key":"1045_CR46","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","volume":"22","author":"VD Gonzalez","year":"2018","unstructured":"Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 2018;22:1875\u201388.","journal-title":"Cell Rep"},{"key":"1045_CR47","doi-asserted-by":"publisher","first-page":"e65005","DOI":"10.1371\/journal.pone.0065005","volume":"8","author":"TC Burch","year":"2013","unstructured":"Burch TC, Watson MT, Nyalwidhe JO. Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells. PLoS ONE. 2013;8:e65005.","journal-title":"PLoS ONE"},{"key":"1045_CR48","doi-asserted-by":"crossref","unstructured":"Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. F1000Res. 2018;7:F1000-Faculty.","DOI":"10.12688\/f1000research.15967.1"},{"key":"1045_CR49","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/ijms26072857","volume":"26","author":"L Zhang","year":"2025","unstructured":"Zhang L, Wang J, Yan Y, Xiang L, Zhai X, Cai L, et al. Vimentin fragmentation and its role in amyloid-beta plaque deposition in Alzheimer\u2019s Disease. Int J Mol Sci. 2025;26:2857.","journal-title":"Int J Mol Sci"},{"key":"1045_CR50","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.7150\/jca.15812","volume":"7","author":"TJ McArdle","year":"2016","unstructured":"McArdle TJ, Ogle BM, Noubissi FK. An in vitro inverted vertical invasion assay to avoid manipulation of rare or sensitive cell types. J Cancer. 2016;7:2333\u201340.","journal-title":"J Cancer"},{"key":"1045_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-23-0402","volume":"14","author":"Z Wang","year":"2024","unstructured":"Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, et al. Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells. Cancer Discov. 2024;14:362\u201379.","journal-title":"Cancer Discov"},{"key":"1045_CR52","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"1045_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, et al. A Systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell. 2018;71:178\u2013190.e8.","journal-title":"Mol Cell"},{"key":"1045_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"1045_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100198","volume":"48","author":"KY Koo","year":"2025","unstructured":"Koo KY, Moon K, Song HS, Lee M-S. Metabolic regulation by p53: Implications for cancer therapy. Mol Cells. 2025;48:100198.","journal-title":"Mol Cells"},{"key":"1045_CR56","doi-asserted-by":"crossref","unstructured":"Semenov O, Daks A, Fedorova O, Shuvalov O, Barlev NA. Opposing roles of wild-type and mutant p53 in the process of epithelial to mesenchymal transition. Front Mol Biosci. 2022;9:928399.","DOI":"10.3389\/fmolb.2022.928399"},{"key":"1045_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102510","volume":"90","author":"W Meng","year":"2024","unstructured":"Meng W, Yu S, Li Y, Wang H, Feng Y, Sun W, et al. Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition. Tissue Cell. 2024;90:102510.","journal-title":"Tissue Cell"},{"key":"1045_CR58","doi-asserted-by":"publisher","first-page":"e2995","DOI":"10.1038\/cddis.2017.376","volume":"8","author":"T Lv","year":"2017","unstructured":"Lv T, Wu X, Sun L, Hu Q, Wan Y, Wang L, et al. p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis. Cell Death Dis. 2017;8:e2995\u2013e2995.","journal-title":"Cell Death Dis"},{"key":"1045_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01276-9","volume":"22","author":"C Ben Hassen","year":"2020","unstructured":"Ben Hassen C, Gutierrez-Pajares JL, Guimaraes C, Guibon R, Pinault M, Fromont G, et al. Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells. Breast Cancer Res. 2020;22:38.","journal-title":"Breast Cancer Res"},{"key":"1045_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2010.04.009","volume":"71","author":"WP Su","year":"2011","unstructured":"Su WP, Chen YT, Lai WW, Lin CC, Yan JJ, Su WC. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer. 2011;71:28\u201333.","journal-title":"Lung Cancer"},{"key":"1045_CR61","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/0008-5472.CAN-23-2889","volume":"84","author":"S Wan","year":"2024","unstructured":"Wan S, He QY, Yang Y, Liu F, Zhang X, Guo X, et al. SPARC stabilizes ApoE to induce cholesterol-dependent invasion and Sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2024;84:1872\u201388.","journal-title":"Cancer Res"},{"key":"1045_CR62","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ajpath.2017.06.016","volume":"187","author":"SK Jayakar","year":"2017","unstructured":"Jayakar SK, Loudig O, Brandwein-Gensler M, Kim RS, Ow TJ, Ustun B, et al. Apolipoprotein E promotes invasion in oral squamous cell carcinoma. Am J Pathol. 2017;187:2259\u201372.","journal-title":"Am J Pathol"},{"key":"1045_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2017.174","volume":"25","author":"KD Sullivan","year":"2018","unstructured":"Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25:133\u201343.","journal-title":"Cell Death Differ"},{"key":"1045_CR64","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1093\/nar\/28.22.4410","volume":"28","author":"K Krause","year":"2000","unstructured":"Krause K, Wasner M, Reinhard W, Haugwitz U, Lange-zu Dohna C, M\u00f6ssner J, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 2000;28:4410\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR65","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.molcel.2004.11.002","volume":"16","author":"SS Clair","year":"2004","unstructured":"Clair SS, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu W-j, Padi A, et al. DNA Damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C Promoter. Mol Cell. 2004;16:725\u201336.","journal-title":"Mol Cell"},{"key":"1045_CR66","doi-asserted-by":"crossref","unstructured":"Fischer M, Quaas M, Nickel A, Engeland K. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21\/CDKN1A and CDE\/CHR promoter sites binding the DREAM complex. Oncotarget 2015;6:41402.","DOI":"10.18632\/oncotarget.6356"},{"key":"1045_CR67","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1128\/MCB.25.17.7423-7431.2005","volume":"25","author":"JS Ho","year":"2005","unstructured":"Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 2005;25:7423\u201331.","journal-title":"Mol Cell Biol"},{"key":"1045_CR68","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/cdd.2014.69","volume":"21","author":"H Li","year":"2014","unstructured":"Li H, Zhang Y, Str\u00f6se A, Tedesco D, Gurova K, Selivanova G. Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ. 2014;21:1493\u2013502.","journal-title":"Cell Death Differ"},{"key":"1045_CR69","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2018.11.011","volume":"176","author":"SH Moon","year":"2019","unstructured":"Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JPT, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176:564\u2013580.e19.","journal-title":"Cell"},{"key":"1045_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30481-7","volume":"13","author":"O Hassin","year":"2022","unstructured":"Hassin O, Nataraj NB, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun. 2022;13:2800.","journal-title":"Nat Commun"},{"key":"1045_CR71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/OTT.S447319","volume":"17","author":"J Chen","year":"2024","unstructured":"Chen J, Zhu H, Chen S, Mi H. Apolipoprotein E is a potential biomarker for predicting cancer prognosis and is correlated with immune infiltration. Onco Targets Ther. 2024;17:199\u2013214.","journal-title":"Onco Targets Ther"},{"key":"1045_CR72","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.tig.2017.08.004","volume":"33","author":"N Skrypek","year":"2017","unstructured":"Skrypek N, Goossens S, De Smedt E, Vandamme N, Berx G. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity. Trends Genet. 2017;33:943\u201359.","journal-title":"Trends Genet"},{"key":"1045_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1045_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.celrep.2015.08.057","volume":"13","author":"G van Niel","year":"2015","unstructured":"van Niel G, Bergam P, Di Cicco A, Hurbain I, Lo Cicero A, Dingli F, et al. Apolipoprotein E regulates amyloid formation within endosomes of pigment cells. Cell Rep. 2015;13:43\u201351.","journal-title":"Cell Rep"},{"key":"1045_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.772315","volume":"9","author":"GK Annor","year":"2021","unstructured":"Annor GK, Elshabassy N, Lundine D, Conde DG, Xiao G, Ellison V, et al. Oligomerization of mutant p53 R273H is not required for gain-of-function chromatin associated activities. Front Cell Dev Biol. 2021;9:772315.","journal-title":"Front Cell Dev Biol"},{"key":"1045_CR76","doi-asserted-by":"publisher","first-page":"e0263463","DOI":"10.1371\/journal.pone.0263463","volume":"17","author":"AA Levesque","year":"2022","unstructured":"Levesque AA, Pappalardo RM, Puli P, Enzor LA, Angeles C. p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor. PLoS ONE. 2022;17:e0263463.","journal-title":"PLoS ONE"},{"key":"1045_CR77","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1073\/pnas.90.8.3319","volume":"90","author":"PN Friedman","year":"1993","unstructured":"Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA. 1993;90:3319\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR78","doi-asserted-by":"crossref","unstructured":"Mehta S, Algie M, Al-Jabry T, McKinney C, Kannan S, Verma CS et al. Critical role for cold shock protein YB-1 in Cytokinesis. Cancers. 2020;12:2473.","DOI":"10.3390\/cancers12092473"},{"key":"1045_CR79","doi-asserted-by":"crossref","unstructured":"Al Bkhetan Z, Wang S. mgikit: demultiplexing toolkit for MGI fastq files. Bioinformatics. 2024;40:btae554.","DOI":"10.1093\/bioinformatics\/btae554"},{"key":"1045_CR80","unstructured":"Cheshire C, R\u00f6nkk\u00f6 T, Patel H, Ladd D, Thiery A, Fields C, et al. nf-core\/cutandrun: nf-core\/cutandrun v3. 2.2 Iridium Ibis. Zenodo. 2024."},{"key":"1045_CR81","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138.","journal-title":"Nat Biotechnol"},{"key":"1045_CR82","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35:316\u20139.","journal-title":"Nat Biotechnol"},{"key":"1045_CR83","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841\u20132.","journal-title":"Bioinformatics"},{"key":"1045_CR84","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576\u201389.","journal-title":"Mol Cell"},{"key":"1045_CR85","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez F, Ryan DP, Gr\u00fcning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160\u20135.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR86","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1101\/gr.220533.117","volume":"27","author":"Z Andrysik","year":"2017","unstructured":"Andrysik Z, Galbraith MD, Guarnieri AL, Zaccara S, Sullivan KD, Pandey A, et al. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. Genome Res. 2017;27:1645\u201357.","journal-title":"Genome Res"},{"key":"1045_CR87","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/onc.2016.502","volume":"36","author":"M Fischer","year":"2017","unstructured":"Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36:3943\u201356.","journal-title":"Oncogene"},{"key":"1045_CR88","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.1093\/nar\/gkt504","volume":"41","author":"D Menendez","year":"2013","unstructured":"Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R, et al. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 2013;41:7286\u2013301.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR89","doi-asserted-by":"publisher","first-page":"8153","DOI":"10.1093\/nar\/gky720","volume":"46","author":"T-AT Nguyen","year":"2018","unstructured":"Nguyen T-AT, Grimm SA, Bushel PR, Li J, Li Y, Bennett BD, et al. Revealing a human p53 universe. Nucleic Acids Res. 2018;46:8153\u201367.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR90","first-page":"82","volume":"40","author":"WL DeLano","year":"2002","unstructured":"DeLano WL. Pymol: an open-source molecular graphics tool. CCP4 Newsl. Protein Crystallogr. 2002;40:82\u201392.","journal-title":"Protein Crystallogr"},{"key":"1045_CR91","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1021\/acs.jcim.8b00462","volume":"58","author":"TS Lee","year":"2018","unstructured":"Lee TS, Cerutti DS, Mermelstein D, Lin C, LeGrand S, Giese TJ, et al. GPU-Accelerated molecular dynamics and free energy methods in Amber18: performance enhancements and new features. J Chem Inf Model. 2018;58:2043\u201350.","journal-title":"J Chem Inf Model"},{"key":"1045_CR92","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926\u201335.","journal-title":"J Chem Phys"},{"key":"1045_CR93","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"1045_CR94","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L. Particle mesh Ewald: an N log (N) method for Ewald sums in large systems. J Chem Phys. 1993;98:10089\u201310089.","journal-title":"J Chem Phys"},{"key":"1045_CR95","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/jcc.540130805","volume":"13","author":"S Miyamoto","year":"1992","unstructured":"Miyamoto S, Kollman PA. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem. 1992;13:952\u201362.","journal-title":"J Comput Chem"},{"key":"1045_CR96","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1021\/ct300284c","volume":"8","author":"LCT Pierce","year":"2012","unstructured":"Pierce LCT, Salomon-Ferrer R, Augusto F. de Oliveira C, McCammon JA, Walker RC. Routine access to millisecond time scale events with accelerated molecular dynamics. J Chem Theory Comput. 2012;8:2997\u20133002.","journal-title":"J Chem Theory Comput"},{"key":"1045_CR97","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33\u201338.","journal-title":"J Mol Graph"},{"key":"1045_CR98","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1074\/jbc.M111.305292","volume":"287","author":"YC Chew","year":"2012","unstructured":"Chew YC, Adhikary G, Wilson GM, Xu W, Eckert RL. Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent. J Biol Chem. 2012;287:16168\u201378.","journal-title":"J Biol Chem"},{"key":"1045_CR99","doi-asserted-by":"publisher","first-page":"10385","DOI":"10.1073\/pnas.1105680108","volume":"108","author":"O Laptenko","year":"2011","unstructured":"Laptenko O, Beckerman R, Freulich E, Prives C. p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci USA. 2011;108:10385\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1045_CR101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"1045_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1045_CR103","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR104","unstructured":"Oliveros JC. Venny. An Interactive Tool for Comparing Lists with Venn\u2019s Diagrams. http:\/\/bioinfogp.cnb.csic.es\/tools\/venny\/index.html. 2007."},{"key":"1045_CR105","doi-asserted-by":"publisher","first-page":"W147","DOI":"10.1093\/nar\/gkw419","volume":"44","author":"S Babicki","year":"2016","unstructured":"Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44:W147\u201353.","journal-title":"Nucleic Acids Res"},{"key":"1045_CR106","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/15376516.2020.1747124","volume":"30","author":"V Adomshick","year":"2020","unstructured":"Adomshick V, Pu Y, Veiga-Lopez A. Automated lipid droplet quantification system for phenotypic analysis of adipocytes using CellProfiler. Toxicol Mech Methods. 2020;30:378\u201387.","journal-title":"Toxicol Mech Methods"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01045-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:03:04Z","timestamp":1786453384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01045-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01045-4","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}